Health Care · Biological Products, (No Diagnostic Substances)

IOVA IOVANCE BIOTHERAPEUTICS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1425205166 filings
Russell 2000

IOVA at a glance

IOVANCE BIOTHERAPEUTICS, INC. (IOVA, SEC CIK 1425205) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported revenue of $263.5 million (up 60.6% from FY2024) and a net loss of $391.0 million. Diluted EPS was -$1.09.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding IOVANCE BIOTHERAPEUTICS, INC. (IOVA) shares worth $2.4 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$263.5M
+60.6% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
32 funds
$2.4B · +4 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Commercial-stage biopharma pioneering individualized tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers
  • New/regulatory: Amtagvi approved in U.S. and Canada, pending UK/Australia 2026 approvals, withdrawn and resubmitting EU MAA in 2026
  • Strategic shift: Transitioned all Amtagvi/lifileucel manufacturing in-house at FDA-approved iCTC facility, ending contract manufacturing early 2026
  • Quantitative highlight: Over 1,500 patients treated with commercial/investigational TIL therapies; iCTC capacity >5,000 patients annually
  • Noteworthy fact: Presented first real-world Amtagvi data (44% ORR) in 2026; advancing Phase 3 TILVANCE-301 trial combining lifileucel with pembrolizumab in frontline melanoma

Risk Factors

  • Cybersecurity risk from internal systems and CROs, requiring increased resources to counter sophisticated threats
  • Dependency on IT infrastructure vulnerable to security breaches impacting business operations
  • Audit Committee oversight on internal controls risks related to cybersecurity threats
  • Management led by VP, Infrastructure and Security with professional cybersecurity certifications tasked with risk management
  • External cybersecurity consultants employed alongside internal team for enhanced protection measures

Management Discussion & Analysis

  • Revenue $263.5M, up 61% YoY; Amtagvi $220.0M (up $116.5M), Proleukin $43.5M (down $17.0M)
  • Cost of sales $173.2M, up 86%; R&D $300.3M, up 9%; SG&A flat at $152.3M; total expenses $666.9M, up 19%
  • Best performing segment: Amtagvi revenue $220.0M, worst: Proleukin revenue down 28% to $43.5M
  • No explicit cash flow, buybacks, dividends data provided; capex details not disclosed
  • Outlook: expect European MAA resubmission in 2026; ongoing clinical trials in multiple indications; focus on global commercial expansion and manufacturing optimization

AI summary of the IOVA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New UPS/DDLPS registrational trial commenced in Q2 2026, increasing clinical execution and regulatory approval risk
  • Manufacturing centralized at iCTC after Minaris exit in January 2026, creating near-term capacity and supply continuity risk
  • FDA accelerated approval for Amtagvi requires confirmatory TILVANCE-301 Phase 3 trial, with failure threatening full approval
  • Cash resources $382.3 million versus $148.6 million net loss for nine months ended September 30, 2026
  • OBBBA changes may reduce ACA Marketplace and Medicaid coverage, potentially constraining reimbursement and product access

Management Discussion & Analysis

  • Revenue $121.5M, up 80% YoY from $67.5M, driven by Amtagvi $101.6M versus $57.5M
  • Proleukin revenue $19.9M, up from $10.0M YoY, the fastest product growth at 99%
  • Net loss $22.3M versus $91.3M YoY, with total costs and expenses $145.4M versus $162.4M
  • Cash, equivalents, investments and restricted cash $382.3M, including $318.4M in short-term investments
  • Operating cash outflow $137.4M for nine months, with $87.9M quarterly net proceeds from stock sales

AI summary of the IOVA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 8.01: Other Events

  • Updated corporate presentation signals refreshed messaging for healthcare conferences, analysts, and investors
  • Exhibit 99.1 contains the substantive investor materials and should be reviewed for pipeline, clinical, or commercial updates

Item EX-99.1: Item EX-99.1

  • 3Q26 revenue ~$382M, up ~80% YoY and ~22% QoQ, demonstrating accelerating Amtagvi commercial adoption
  • Full-year 2026 revenue guidance $410M-$420M, midpoint up $55M or ~15% versus prior guidance of $350M-$370M
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 ended September 30, 2026 financial results announced by Iovance Biotherapeutics
  • Update on recent corporate and operating developments included in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $121.5M, up ~80% YoY, with U.S. Amtagvi revenue ~$102M, confirming accelerating commercial adoption
  • Gross margin ~60%, up from 56% in Q2, while R&D expense declined ~16% sequentially, improving operating leverage
Filed Oct 29, 2026Full analysis →

Item 8.01: Other Events

  • Updated Phase 2 IOV-LUN-202 results for lifileucel in previously treated metastatic non-squamous NSCLC
  • Cohorts 1 and 2 data may inform lifileucel efficacy and safety assessment in lung cancer

Item EX-99.1: Item EX-99.1

  • Lifileucel ORR 24.6% in 69 previously treated non-squamous mNSCLC patients, consistent with prior 25.6% result
  • KRAS wild-type ORR 43.3% versus 11.4% for KRAS-mutant disease, with both complete responses in KRAS wild-type tumors

AI summaries of IOVA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IOVA

Don't miss the next IOVA filing

  • Alerts as it files. A push when IOVA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IOVA, by share count.
  • Ask anything. An AI agent that reads every IOVA filing and answers with sources.

IOVA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Vogt Frederick GFNov 11, 2026$8.09
Vogt Frederick GMNov 11, 2026$7.55
Vogt Frederick GMNov 11, 2026-
Kirby Daniel GordonMNov 10, 2026-
Kirby Daniel GordonMNov 10, 2026-
Kirby Daniel GordonFNov 10, 2026$8.08
Roche Corleen M.FNov 6, 2026$8.04
Roche Corleen M.MNov 6, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$164.1M$263.5M
Operating Income-$460.6M-$395.3M-$403.4M
Net Income-$444.0M-$372.2M-$391.0M
Op. Margin--240.9%-153.1%
Net Margin--226.8%-148.4%
Balance Sheet
Total Assets-$910.4M$913.2M
Equity-$710.4M$698.6M
ROE--52.4%-56.0%
Per Share
EPS$-1.89$-1.28$-1.09
Cash Flow
Operating CF-$361.8M-$353.0M-$302.4M
CapEx-$11.1M$33.8M

Source: XBRL data in IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IOVA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IOVA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$2.35B
Q2 202628$702.5M
Q1 202629$529.4M
Q4 202528$389.0M
Q3 202527$241.2M
Q2 202528$196.8M
Q1 202526$243.3M
Q4 202420$404.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 218 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IOVA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
4Nov 12, 2026--
4Nov 10, 2026--
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KNov 5, 2026Analysis-
8-KOct 29, 2026Analysis-
8-KOct 5, 2026Analysis-
4Oct 2, 2026--
8-KSep 29, 2026Analysis-
4Sep 10, 2026--
4Sep 10, 2026--
4Sep 10, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Aug 12, 2026--
4Aug 10, 2026--
SC 13GAug 7, 2026-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KJul 2, 2026Analysis-
4Jun 18, 2026--
4Jun 18, 2026--

Related Health Care companies

All Health Care →

IOVA SEC filings: frequently asked questions

Which institutions hold IOVA stock?

As of September 30, 2026, the largest IOVANCE BIOTHERAPEUTICS, INC. (IOVA) holders among the 13F filers tracked by SignalX were BlackRock ($561.7 million), State Street Corp ($321.5 million), Vanguard Capital Management LLC ($272.6 million), Two Sigma Investments ($221.8 million), Vanguard Portfolio Management LLC ($182.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was IOVA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported revenue of $263.5 million (up 60.6% from FY2024) and a net loss of $391.0 million. Diluted EPS was -$1.09. The figures come from the XBRL data in the 10-K.

What are the main risks in IOVA's latest 10-K?

In the 10-K filed February 24, 2026, IOVANCE BIOTHERAPEUTICS, INC. (IOVA) flagged: Cybersecurity risk from internal systems and CROs, requiring increased resources to counter sophisticated threats. Dependency on IT infrastructure vulnerable to security breaches impacting business operations. (AI summary of the Risk Factors section.)

What did IOVA report in its latest 8-K?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K on November 5, 2026 reporting Item 8.01 (Other Events). Updated corporate presentation signals refreshed messaging for healthcare conferences, analysts, and investors.

What are the latest IOVA SEC filings?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is IOVA's SEC CIK number?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s SEC Central Index Key (CIK) is 1425205. EDGAR lists every IOVA filing under that number.

Ask anything about IOVA

The research agent reads IOVA's filings, financials, insider trades and 13F holders, then answers with sources.